Company Description
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases.
The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality.
It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.
The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 216 |
| CEO | Paul Badawi |
Contact Details
Address: 4040 Campbell Avenue, Suite 100 Menlo Park, California 94025 United States | |
| Phone | 877 266 1144 |
| Website | sightsciences.com |
Stock Details
| Ticker Symbol | SGHT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001531177 |
| CUSIP Number | 82657M105 |
| ISIN Number | US82657M1053 |
| Employer ID | 80-0625749 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Badawi | Co-Founder, President, Chief Executive Officer and Director |
| Dr. David Badawi M.D. | Co-Founder, Chief Technology Officer and Director |
| Alison Perry Bauerlein | Chief Financial Officer and Treasurer |
| Matthew W. Link | Chief Commercial Officer |
| Brenton Taylor | Executive Vice President of Operations |
| Jeremy B. Hayden J.D. | Chief Legal Officer |
| Steve R. Tamayo Jr. | Vice President and Chief Ethics and Compliance Officer |
| Dr. Reay H. Brown M.D. | Chief Medical Officer |
| Dr. Manohar K. Raheja Ph.D. | Executive Vice President of Research and Development |
| Stephen B. Thau J.D. | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 2, 2025 | 144 | Filing |
| Apr 2, 2025 | 144 | Filing |
| Apr 2, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |
| Mar 13, 2025 | SCHEDULE 13D/A | Filing |
| Mar 7, 2025 | 10-K | Annual Report |